As an industry, pharmaceutical marketers spend a significant amount of time, money, and effort to motivate and get consumers and patients to the pharmacy – the fill.

However, while we spend a lot of time thinking about marketing and getting the suitable patients to the doctor’s office, in many cases, we don’t think about the “last mile” and what happens at the pharmacy setting when they have the final conversion from Rx to treatment in hand (or bag). Do they have the correct information to alleviate potential concerns about side effects? Do they have the right and most recent information related to their coverage and benefits for their first fill – and subsequent fills?

As an industry, brands may lose anywhere from 20% to 40% of patients between the Rx and the pharmacy fill. How can brands partner with physicians, patients, and pharmacies to reduce this leakage in the system?

As GenAI evolves at a record pace, pharma commercial teams must keep pace without losing sight of the overall business strategy. Understanding, testing, and extracting value from GenAI is critical for the majority of commercial teams across the pharmaceutical, bio, and life sciences landscape today.

The potential impact of GenAI within pharma ranges from MLR, creative, audience building, targeting, patient support programs, field force content optimization, as well as the broader category of customer experience programs with both patients and physicians.

With more literature about new treatments, devices, patient types… it’s no wonder that treaters remain overwhelmed with information. How can you Cut Through The Clutter?

In this project, The DHC Group and BGB Group surveyed over 100 Sermo network HCPs from a range of highly scientific and complex therapeutic areas including oncology, neurology, and immunology, on their current digital content consumption habits, preferences, and hopes for the future.